Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Current status of immunological therapies for prostate cancer. Curr Opin Urol (2010) 1.06

Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00

Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am (2013) 0.92

Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81

Commentary on early hormonal therapy for PSA only recurrence after radical prostatectomy--success towards survival or antidote to anxiety? J Urol (2008) 0.75

Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73

Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol (2007) 3.94

Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13

Outcomes of endodontic therapy in general practice: a study by the Practitioners Engaged in Applied Research and Learning Network. J Am Dent Assoc (2012) 2.90

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77

Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54

Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol (2003) 2.40

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res (2007) 2.34

Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate (2008) 2.16

Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol (2003) 2.10

Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol (2003) 2.06

Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol (2010) 2.05

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol (2002) 2.02

Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene (2004) 2.02

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2004) 1.91

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol (2008) 1.91

The association of body mass index and prostate-specific antigen in a population-based study. Cancer (2005) 1.85

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80

Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res (2010) 1.77

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol (2007) 1.71

Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer (2008) 1.71

Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer (2007) 1.70

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59

Factors predicting prostatic biopsy Gleason sum under grading. J Urol (2009) 1.59

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer (2006) 1.58

ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther (2011) 1.56

Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene (2002) 1.55

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54

Improving the performance of physiologic hot flash measures with support vector machines. Psychophysiology (2009) 1.54

A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care (2010) 1.52

Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol (2005) 1.50

Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy. Eur Urol (2012) 1.50

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol (2010) 1.45

Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology (2009) 1.44

Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol (2006) 1.43

Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.41

Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res (2008) 1.35

Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.33

Optimized prostate biopsy via a statistical atlas of cancer spatial distribution. Med Image Anal (2004) 1.33

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol (2004) 1.31

Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys (2008) 1.27

Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer (2007) 1.27

PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res (2003) 1.25

Targeted prostate biopsy using statistical image analysis. IEEE Trans Med Imaging (2007) 1.25

Hispanic acculturation and utilization of cervical cancer screening in the US. Prev Med (2005) 1.25

Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25

Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res (2006) 1.22

Design of fenofibrate microemulsion for improved bioavailability. Int J Pharm (2011) 1.22

LAMP: A Database Linking Antimicrobial Peptides. PLoS One (2013) 1.21

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int (2010) 1.20

The burden of prostate cancer in Asian nations. J Carcinog (2012) 1.19

Low wintertime vitamin D levels in a sample of healthy young adults of diverse ancestry living in the Toronto area: associations with vitamin D intake and skin pigmentation. BMC Public Health (2008) 1.18

Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology (2009) 1.18

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery (2002) 1.17

HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer (2012) 1.17

Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17